The Long Run with Luke Timmerman
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Latest episodes
Jul 24, 2023 • 1h 3min
Ep140: Yung Lie on Supporting Young Scientists with Bold, Brave Ideas
Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
Jul 10, 2023 • 1h 8min
Ep139: Kevin Conroy on Early Detection of Cancer
Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.
Jun 27, 2023 • 1h
Ep138: Jodie Morrison on Becoming a Biotech CEO
Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
Jun 14, 2023 • 57min
Ep137: Aaron Ring on Immunotherapy for Cancer & More
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
May 30, 2023 • 53min
Ep136: Deborah Palestrant on Building Biotech Startups
Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
May 8, 2023 • 1h 4min
Ep135: John Maraganore on Developing a New Class of Medicines
John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.
Apr 24, 2023 • 1h 16min
Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Apr 12, 2023 • 1h 11min
Ep133: Catherine Stehman-Breen on Epigenetic Editing Therapies
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Mar 28, 2023 • 1h 6min
Ep132: Eric Dobmeier on Treating Kidney Disease
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Mar 14, 2023 • 1h 6min
Ep131: Ryan Watts on Neuroscience Drug R&D
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
